The leukotriene B 4 receptors BLT1 and BLT2 as potential therapeutic targets
Immunological Reviews · 2023
DOI: 10.1111/imr.13196 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunological Reviews, 2023. Verfasst von Takehiko Yokomizo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Graduate School of Medicine, Juntendo University, Tokyo, Japan. Hauptthemen laut MEDLINE: Leukotriene B4, Asthma. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 129 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development, Ministry of Education, Culture, Sports, Science and Technology, Takeda Science Foundation.
Abstract (Originalsprache)
Leukotriene B 4 (LTB 4 ) was recognized as an arachidonate‐derived chemotactic factor for inflammatory cells and an important drug target even before the molecular identification of its receptors. We cloned the high‐ and low‐affinity LTB 4 receptors, BLT1 and BLT2, respectively, and examined their functions by generating and studying gene‐targeted mice. BLT1 is involved in the pathogenesis of various inflammatory and immune diseases, including asthma, psoriasis, contact dermatitis, allergic conjunctivitis, age‐related macular degeneration, and immune complex‐mediated glomerulonephritis. Meanwhile, BLT2 is a high‐affinity receptor for 12‐hydroxyheptadecatrienoic acid, which is involved in the maintenance of dermal and intestinal barrier function, and the acceleration of skin and corneal wound healing. Thus, BLT1 antagonists and BLT2 agonists are promising candidates in the treatment of inflammatory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
- Institute of Microbial Chemistry, Tokyo, Japan.
- Department of Lipid Signaling, National Center for Global Health and Medicine, Tokyo, Japan.
ORCID-Profile: Takehiko Yokomizo
Förderung
- Japan Agency for Medical Research and Development
- Ministry of Education, Culture, Sports, Science and Technology
- Takeda Science Foundation
Zitieren
APA
Yokomizo, T., & Shimizu, T. (2023). The leukotriene B 4 receptors BLT1 and BLT2 as potential therapeutic targets. Immunological Reviews. https://doi.org/10.1111/imr.13196
Vancouver
Yokomizo T, Shimizu T. The leukotriene B 4 receptors BLT1 and BLT2 as potential therapeutic targets. Immunological Reviews. 2023. doi:10.1111/imr.13196
BibTeX
@article{Yokomizo2023,
author = {Yokomizo, Takehiko and Shimizu, Takao},
title = {The leukotriene B 4 receptors BLT1 and BLT2 as potential therapeutic targets},
journal = {Immunological Reviews},
year = {2023},
doi = {10.1111/imr.13196}
}
EUVIMED